鼻咽癌患者放疗后中重度口干恢复预测列线图的开发与验证
本研究基于223例病理诊断为鼻咽癌的患者构建并内部验证预测模型,采用LASSO回归筛选变量、Cox比例风险回归建立列线图,外部验证队列78例。模型纳入年龄、性别、放疗后口干问卷评分及腮腺、下颌下腺、舌下腺的平均剂量,内部与外部验证C指数分别为0.729和0.736,校准良好,决策曲线分析显示临床有用。下颌下腺保留组12个月和24个月中重度口干率均低于未保留组。
要点
- 列线图纳入年龄、性别、放疗后XQ评分及腮腺、下颌下腺、舌下腺平均剂量。
- 下颌下腺保留组12个月中重度口干率28.4% vs 未保留组56.8%,HR 1.84(95%CI 1.412-2.397,p=0.000)。
- 24个月两组中重度口干剩余时间限制平均生存时间差为5.757个月(95%CI 3.863-7.651,p=0.000)。
核心结论
- 开发的列线图纳入年龄、性别、放疗后口干问卷评分及腮腺、下颌下腺、舌下腺的平均剂量,可用于预测鼻咽癌患者放疗后中重度口干的恢复。
- 保留下颌下腺对患者恢复高度重要。
研究设计与样本
- 研究构建并内部验证预测模型,原发队列包括2016年2月至2019年12月经病理诊断为鼻咽癌的223例患者,外部验证队列包括78例患者。
- 采用LASSO回归模型识别临床因素及相关变量(放疗前和放疗后即刻的口干问卷评分,以及腮腺、下颌下腺、舌下腺、管状腺和口腔的平均剂量),采用Cox比例风险回归分析建立预测模型并以列线图呈现。
- 对模型的校准度、区分度和临床有用性进行了评估。
主要发现
- 由于训练队列中区分度和校准度更好,年龄、性别、放疗后口干问卷评分以及腮腺、下颌下腺和管状腺的平均剂量被纳入个体化预测模型,C指数为0.741(95%CI 0.717-0.765)。
- 内部验证和外部验证队列中列线图区分度良好,C指数分别为0.729(95%CI 0.692-0.766)和0.736(95%CI 0.702-0.770),校准良好。
- 决策曲线分析显示列线图具有临床有用性。
- 两组24个月时中重度口干剩余时间的限制平均生存时间差为5.757个月(95%CI 3.863-7.651,p=0.000)。
关键数值与推荐
- 预测模型纳入变量:年龄、性别、放疗后口干问卷评分、腮腺平均剂量、下颌下腺平均剂量、管状腺平均剂量。
- 训练队列C指数0.741(95%CI 0.717-0.765),内部验证C指数0.729(95%CI 0.692-0.766),外部验证C指数0.736(95%CI 0.702-0.770)。
- 下颌下腺保留组24个月中重度口干率5.2%(95%CI 0.029-0.093) vs 未保留组12.5%(95%CI 0.070-0.223),HR 1.84(95%CI 1.412-2.397,p=0.000)。
- 24个月时两组中重度口干剩余时间的限制平均生存时间差为5.757个月(95%CI 3.863-7.651,p=0.000)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Aim to create and validate a comprehensive nomogram capable of accurately predicting the transition from moderate-severe to normal-mild xerostomia post-radiotherapy (postRT) in patients with nasopharyngeal carcinoma (NPC). MATERIALS AND METHODS: We constructed and internally verified a prediction model using a primary cohort comprising 223 patients who were pathologically diagnosed with NPC from February 2016 to December 2019. LASSO regression model was used to identify the clinical factors and relevant variables (the pre-radiotherapy (XQ-preRT) and immediate post-radiotherapy (XQ-postRT) xerostomia questionnaire scores, as well as the mean dose (Dmean) delivered to the parotid gland (PG), submandibular gland (SMG), sublingual gland (SLG), tubarial gland (TG), and oral cavity). Cox proportional hazards regression analysis was performed to develop the prediction model, which was presented as a nomogram. The models' performance with regard to calibration, discrimination, and clinical usefulness was evaluated. The external validation cohort comprised 78 patients. RESULTS: Due to better discrimination and calibration in the training cohort, age, gender, XQ-postRT, and Dmean of PG, SMG, and TG were included in the individualized prediction model (C-index of 0.741 (95% CI:0.717 to 0.765). Verification of the nomogram's performance in internal and external validation cohorts revealed good discrimination (C-index of 0.729 (0.692 to 0.766) and 0.736 (0.702 to 0.770), respectively) and calibration. Decision curve analysis revealed that the nomogram was clinically useful. The 12-month and 24-month moderate-severe xerostomia rate was statistically lower in the SMG-spared arm (28.4% (0.230 to 35.2) and 5.2% (0.029 to 0.093), respectively) than that in SMG-unspared arm (56.8% (0.474 to 0.672) and 12.5% (0.070 to 0.223), respectively), with an HR of 1.84 (95%CI: 1.412 to 2.397, p = 0.000). The difference in restricted mean survival time for remaining moderate-severe xerostomia between the two arms at 24 months was 5.757 months (95% CI, 3.863 to 7.651; p = 0.000). CONCLUSION: The developed nomogram, incorporating age, gender, XQ-postRT, and Dmean to PG, SMG, and TG, can be used for predicting recovery from moderate-severe xerostomia post-radiotherapy in NPC patients. Sparing SMG is highly important for the patient's recovery.
引用
- Zhao DW, Teng F, Meng LL, et al. Development and validation of a nomogram for prediction of recovery from moderate-severe xerostomia post-radiotherapy in nasopharyngeal carcinoma patients. Radiother Oncol. 2023. PMID: 37120102. doi:10.1016/j.radonc.2023.109683
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。